

END-TO-END
SOLUTIONS FOR
GENOMICS (NGS)
IN
CANCER,
NEWBORN
SCREENING &
INFECTIOUS
DISEASES



tNGS LSD Panel



tNGS Cancer Panels



Cancer 50



BRCA Panel



Lung Cancer Panel



Colorectal Cancer Panel



Sepsis/AMR










Newborn Screening


tNGS LSD Panel

Lysosomal storage disorder (LSD) is an inborn error of metabolism. It is a group of diseases that are caused by certain improper or non-functional lysosome enzymes. This kit is based on the Next Generation sequencing (Massive Parallel Sequencing) that captures and amplifies the 23 target genes responsible for LSD. The sequencing results can help clinicians to identify any possible mutations in genes associated with 23 common LSDs at the same time.

Key features

-  No extra reagents (Library preparation Kit) required
-  No additional bioinformatician required
-  Cost-effective
-  Semi-automated pipeline
-  Short processing time
-  Optimized clinical management
-  Shorter TAT helps to reduce the psychological burden & provides appropriate genetic counselling to parents

Work flow









Diseases covered

- Gaucher
- Niemann-Pick A/B/C
- Morquio-A/B
- Pompe
- Fabry
- Tay-Sachs
- GM1 Gangliosidosis
- Maroteaux-Lamy
- Hurler
- Hunter
- Sanphilippo-A/B
- Sandhoff
- NCL-2
- Mucopolipidosis-II alpha/beta
- Mucopolipidosis-III alpha/beta
- Metachromatic leukodystrophy
- Krabbe diseases


Cancer 50

tNGS for Cancer 50 test can be performed on solid tumor material from the patient. This test identifies the mutations across the 50 genes and helps in choosing precision medicine cancer therapy for the patient.

Key features

-  No extra reagents (Library preparation Kit) required
-  No additional bioinformatician required
-  Cost-effective
-  Semi-automated pipeline
-  Short processing time
-  Optimized clinical management

Work flow









Genes Covered

- | | | | | |
|--|---|---|--|--|
| <ul style="list-style-type: none"> • ABL1 • AKT1 • ALK • APC • ATM • BRAF • CDH1 • CDKN2A • CSF1R • CTNNB1 | <ul style="list-style-type: none"> • EGFR • ERBB2 • ERBB4 • EZH2 • FBXW7 • FGFR1 • FGFR2 • FGFR3 • FLT3 • GNA11 | <ul style="list-style-type: none"> • GNAQ • GNAS • HNF1A • HRAS • IDH1 • IDH2 • JAK2 • JAK3 • KDR • KIT | <ul style="list-style-type: none"> • KRAS • MET • MLH1 • MPL • NOTCH1 • NPM1 • NRAS • PDGFRA • PIK3CA • PTEN | <ul style="list-style-type: none"> • PTPN11 • RB1 • RET • SMAD4 • SMARCB1 • SMO • SRC • STK11 • TP53 • VHK |
|--|---|---|--|--|


BRCA Panel

The kit is based on the Next Generation Sequencing (Massive Parallel Sequencing) that captures and amplifies the 14 target genes responsible for BRCA diagnosis and therapy. The sequencing results can help clinicians to identify any possible mutations in key genes associated with BRCA cancer at the same time.

Key features

-  No extra reagents (Library preparation Kit) required
-  No additional bioinformatician required
-  Cost-effective
-  Semi-automated pipeline
-  Short processing time
-  Optimized clinical management

Work flow









Genes Covered

- ERBB2
- PIK3CA
- BRAC1/2
- ESR1
- PTEN
- AKT1
- MDM2
- ERBB3
- NF1
- MLH1
- MSH2
- PMS1
- PMS2


Lung Cancer Panel

The kit is based on the Next Generation Sequencing (Massive Parallel Sequencing) that captures and amplifies the 22 target genes.

Key features

-  No extra reagents (Library preparation Kit) required
-  No additional bioinformatician required
-  Cost-effective
-  Semi-automated pipeline
-  Short processing time
-  Optimized clinical management

Work flow









Genes Covered

- KRAS
- EGFR
- BRAF
- PIK3CA
- AKT1
- ERBB2
- PTEN
- NRAS
- STK11
- MAP2K1
- ALK
- DDR2
- CTNNB1
- MET
- STP53
- SMAD4
- FBX7
- FGFR3
- NOTCH1
- ERBB4
- FGFR1
- FGFR2

Colorectal Cancer Panel

The kit is based on the Next Generation Sequencing (Massive Parallel Sequencing) that captures and amplifies the 22 target genes.

Key features

-  No extra reagents (Library preparation Kit) required
-  No additional bioinformatician required
-  Cost-effective
-  Semi-automated pipeline
-  Short processing time
-  Optimized clinical management

Work flow










Genes Covered

- KRAS
- EGFR
- BRAF
- PIK3CA
- AKT1
- ERBB2
- PTEN
- NRAS
- STK11
- MAP2K1
- ALK
- DDR2
- CTNNB1
- MET
- STP53
- SMAD4
- FBX7
- FGFR3
- NOTCH1
- ERBB4
- FGFR1
- FGFR2

Sepsis Panel

The kit is based on the Next Generation Sequencing (Massive Parallel Sequencing) that captures and amplifies the 16 common sepsis causing pathogens. The sequencing results can help clinicians to identify any possible microorganism associated with sepsis.

Key features

-  No extra reagents (Library preparation Kit) required
-  No additional bioinformatician required
-  Cost-effective
-  Semi-automated pipeline
-  Short processing time
-  Optimized clinical management
-  Shorter TAT helps to reduce the psychological burden & provides appropriate genetic counselling to parents

Work flow










Pathogens Covered

- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Pseudomonas aeruginosa*
- *Acinetobacter baumannii*
- *Neisseria meningitidis*
- *Haemophilus influenza*
- *Streptococcus pneumoniae*
- *Streptococcus suis*
- *Enterococcus faecalis*
- *Proteus mirabilis*
- *Proteus vulgaris*
- *Bacteroides fragilis*
- *Streptococcus pyogenes*
- *Staphylococcus aureus*
- *Clostridium difficile*
- *Histoplasma capsulatum*

Newborn Screening

Neonatal screening or Newborn Screening involves the screening of newborns in the first days of their lives for inborn errors of metabolism and certain disorders that can hinder the normal development of the baby. These disorders are not apparent at the time of the baby's birth but have potential to cause permanent neurological, cognitive, tactile and physical damage in the child. This kit is based on the Next Generation Sequencing (Massive Parallel Sequencing) that captures and amplifies the 9 common newborn disorders.

Key features

-  No extra reagents (Library preparation Kit) required
-  No additional bioinformatician required
-  Cost-effective
-  Semi-automated pipeline
-  Short processing time
-  Optimized clinical management
-  Shorter TAT helps to reduce the psychological burden & provides appropriate genetic counselling to parents

Work flow



Diseases Covered

- Congenital hypothyroidism (CH)
 - Congenital adrenal hyperplasia (CAH) (21-Hydroxylase-Deficiency)
 - Phenylketonurie (PKU)
 - Sickle cell disease (HbSS,
 - HbS/β-thalassemia, HbS/C)
 - Galactosemia
- Cystic Fibrosis (CF)
 - Spinal Muscular Atrophy (SMA)
 - Phenylketonurie (PKU)
 - Severe Combined Immunodeficiency (SCID)